Autoimmune diseases often present with cutaneous symptoms that contribute to dysfunction,
disfigurement, and in many cases, reduced quality-of-life. Unfortunately, treatment options …

Introduction Biologics serve as a cornerstone in psoriasis treatment, with low disease activity
or sometimes even clinical remission as a realistic treatment outcome. So far, it is unclear …

Study design After one year of maintained PASI-100, the between-dose intervals were
progressively extended, stepping up 3–4 days each month, up to a 21-or 28-day interval …

Dose reduction (DR) of biologics, where possible, seems promising for more efficient use of
expensive biologics. For implementation of DR strategies, it is essential to get insight in …

Background Dose reduction of biologics for psoriasis is applied in daily practice, although
guidelines are lacking. Striving for clear criteria is important, as it leads to a consistent …

Psoriasis is an inflammatory immune-mediated skin disease that significantly impacts
physical and psychological well-being. Adalimumab (ADA), a tumor necrosis factor (TNF)-α …

4 Rivitti-Machado MC, Toma TJ, Pompeu VMA et al. Epidermolysis bullosa pruriginosa
associated with folliculitis decalvans: case report and review of the literature. Skin …

Background Psoriasis is a chronic, inflammatory skin disease with autoimmune
characteristics. Recent research has made significant progress in the field of psoriasis …

Psoriasis is a chronic disease and often requires long‐term treatment, especially in patients
with moderate‐to‐severe psoriasis. It remains controversial whether the doses of systemic …

Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors
(i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The …